Questions Roll In As UDI Expands In US; Debate Over System Adoption Continues
This article was originally published in SRA
While the US Food and Drug Administration's requirements relating to unique device identification (UDI) first took effect in 2014, the UDI mandate remains a dynamic issue for the medtech industry as more and more devices become subject to UDI labeling and database submissions each year.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.